Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.65+0.02 (+1.23%)
Close on Nov 13, 2026Market cap $298.77MP/E –Yield –
Century Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Century Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $74.46M, down 29.3% year over year. For fiscal 2025 it was $95.67M, down 10.8% from the year before. The highest annual figure on record is $107.24M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.67M | -10.8% |
| FY2024 | Dec 31, 2024 | $107.24M | +15.7% |
| FY2023 | Dec 31, 2023 | $92.71M | -4.6% |
| FY2022 | Dec 31, 2022 | $97.17M | +28.5% |
| FY2021 | Dec 31, 2021 | $75.65M | +90.6% |
| FY2020 | Dec 31, 2020 | $39.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.06M | -19.8% |
| Q2 FY2026 | Jun 30, 2026 | $19.60M | -27.0% |
| Q1 FY2026 | Mar 31, 2026 | $17.11M | -35.6% |
| Q4 FY2025 | Dec 31, 2025 | $19.70M | -33.0% |
| Q3 FY2025 | Sep 30, 2025 | $22.53M | -17.3% |
| Q2 FY2025 | Jun 30, 2025 | $26.86M | -1.3% |
| Q1 FY2025 | Mar 31, 2025 | $26.58M | +13.5% |
| Q4 FY2024 | Dec 31, 2024 | $29.38M | +31.8% |
| Q3 FY2024 | Sep 30, 2024 | $27.23M | +19.5% |
| Q2 FY2024 | Jun 30, 2024 | $27.22M | +19.8% |
| Q1 FY2024 | Mar 31, 2024 | $23.42M | -5.9% |
| Q4 FY2023 | Dec 31, 2023 | $22.30M | -12.9% |
| Q3 FY2023 | Sep 30, 2023 | $22.79M | -12.0% |
| Q2 FY2023 | Jun 30, 2023 | $22.73M | -7.2% |
| Q1 FY2023 | Mar 31, 2023 | $24.90M | +17.5% |
| Q4 FY2022 | Dec 31, 2022 | $25.59M | +17.4% |
| Q3 FY2022 | Sep 30, 2022 | $25.90M | +32.5% |
| Q2 FY2022 | Jun 30, 2022 | $24.49M | +29.4% |
| Q1 FY2022 | Mar 31, 2022 | $21.20M | +37.9% |
| Q4 FY2021 | Dec 31, 2021 | $21.80M | +75.2% |
| Q3 FY2021 | Sep 30, 2021 | $19.55M | +80.8% |
| Q2 FY2021 | Jun 30, 2021 | $18.93M | +123.2% |
| Q1 FY2021 | Mar 31, 2021 | $15.37M | – |
| Q4 FY2020 | Dec 31, 2020 | $12.44M | – |
| Q3 FY2020 | Sep 30, 2020 | $10.81M | – |
| Q2 FY2020 | Jun 30, 2020 | $8.48M | – |
See a number that looks wrong?